Ali MT, Yucel E, Bouras S, Wang L, Fei HW, Halpern EF, Scherrer-Crosbie M (2016) Myocardial Strain Is Associated with Adverse Clinical Cardiac Events in Patients Treated with Anthracyclines J Am Soc Echocardiogr 29:522-527 e523 doi:10.1016/j.echo.2016.02.018
Biersmith MA, Tong MS, Guha A, Simonetti OP, Addison D (2020) Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies J Am Heart Assoc 9:e013755 doi:10.1161/JAHA.119.013755
Bovelli D, Plataniotis G, Roila F, Group EGW (2010) Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines Ann Oncol 21 Suppl 5:v277-282 doi:10.1093/annonc/mdq200
Caspi O, Aronson D (2019) Surviving Cancer without a Broken Heart Rambam Maimonides Med J 10 doi:10.5041/RMMJ.10366
Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH (2017a) Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1 J Am Coll Cardiol 70:2536-2551 doi:10.1016/j.jacc.2017.09.1096
Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH (2017b) Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2 J Am Coll Cardiol 70:2552-2565 doi:10.1016/j.jacc.2017.09.1095
Chau T. Dang AFY, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis (2016) Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter Journal of Clinical Oncology
Curigliano G et al. (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines Ann Oncol 23 Suppl 7:vii155-166 doi:10.1093/annonc/mds293
Curigliano G et al. (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations Ann Oncol 31:171-190 doi:10.1016/j.annonc.2019.10.023
Eschenhagen T et al. (2011) Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13:1-10 doi:10.1093/eurjhf/hfq213
Fallah-Rad N et al. (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57:2263-2270 doi:10.1016/j.jacc.2010.11.063
Force T, Kolaja KL (2011) Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10:111-126 doi:10.1038/nrd3252
Guglin M, Aljayeh M, Saiyad S, Ali R, Curtis AB (2009) Introducing a new entity: chemotherapy-induced arrhythmia Europace 11:1579-1586 doi:10.1093/europace/eup300
Hersh MR, Linn W, Kuhn JG, Von Hoff DD (1986) Electrocardiographic monitoring of patients receiving phase I cancer chemotherapy Cancer Treat Rep 70:349-352
Izzedine H et al. (2009) Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol 20:807-815 doi:10.1093/annonc/mdn713
Jones AL et al. (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring British Journal of Cancer 100:684-692 doi:10.1038/sj.bjc.6604909
Kotwinski P et al. (2016) Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer PLoS One 11:e0165262 doi:10.1371/journal.pone.0165262
Lal H, Kolaja KL, Force T (2013) Cancer genetics and the cardiotoxicity of the therapeutics J Am Coll Cardiol 61:267-274 doi:10.1016/j.jacc.2012.05.066
Lopez-Sendon J et al. (2020) Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry Eur Heart J 41:1720-1729 doi:10.1093/eurheartj/ehaa006
Lynce F et al. (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study Breast Cancer Res Treat 175:595-603 doi:10.1007/s10549-019-05191-2
Meinardi MT, van der Graaf WT, van Veldhuisen DJ, Gietema JA, de Vries EG, Sleijfer DT (1999) Detection of anthracycline-induced cardiotoxicity Cancer Treat Rev 25:237-247 doi:10.1053/ctrv.1999.0128
Michel L, Schadendorf D, Rassaf T (2020) Oncocardiology: new challenges, new opportunities Herz doi:10.1007/s00059-020-04951-x
Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F (2014) Arterial hypertension and cancer Int J Cancer 134:2269-2277 doi:10.1002/ijc.28334
Negishi T, Thavendiranathan P, Negishi K, Marwick TH, investigators S (2018) Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial JACC Cardiovasc Imaging 11:1098-1105 doi:10.1016/j.jcmg.2018.03.019
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 25:3808-3815 doi:10.1200/JCO.2006.10.4976
Plana JC et al. (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Eur Heart J Cardiovasc Imaging 15:1063-1093 doi:10.1093/ehjci/jeu192
Ponikowski P et al. (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 18:891-975 doi:10.1002/ejhf.592
Prisco D, D’Elios MM, Cenci C, Ciucciarelli L, Tamburini C (2014) Cardiovascular oncology: a new discipline inside internal medicine? Internal and Emergency Medicine 9:359-364 doi:10.1007/s11739-014-1064-9
Santoro C et al. (2017) 2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility Eur Heart J Cardiovasc Imaging 18:930-936 doi:10.1093/ehjci/jex033
Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, Berger JS (2013) Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects J Am Coll Cardiol 61:1736-1743 doi:10.1016/j.jacc.2013.01.054
Sawaya H et al. (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107:1375-1380 doi:10.1016/j.amjcard.2011.01.006
Sawaya H et al. (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab Circ Cardiovasc Imaging 5:596-603 doi:10.1161/CIRCIMAGING.112.973321
SERVICES USDOHAH, Health NIo, Institute NC (2010) Common Terminology Criteria for Adverse Events (CTCAE) 4.03:4-6, 41-42, 66, 69
Stevens PL, Lenihan DJ (2015) Cardiotoxicity due to Chemotherapy: the Role of Biomarkers Curr Cardiol Rep 17:603 doi:10.1007/s11886-015-0603-y
Sugimoto T et al. (2017) Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study Eur Heart J Cardiovasc Imaging 18:833-840 doi:10.1093/ehjci/jex140
Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH (2014) Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy Journal of the American College of Cardiology 63:2751-2768 doi:10.1016/j.jacc.2014.01.073
Zamorano JL et al. (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines European Heart Journal 37:2768